Luminex has since fixed the problem with a software update but a similar issue with non-specific amplification has also affected two targets on BioFire's GI panel.
In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.
The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.
Despite a recent positive economic modeling study, the debate over appropriate use of the ME panel seems likely to continue until more outcomes studies are conducted.
Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.
